Clinical Trial Update: C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating C11-Sodium Acetate PET/CT imaging for metastatic disease in intermediate-to-high risk prostate adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• C11-Sodium Acetate (Sodium acetate labeled with Carbon-11)

Snippet

Sponsor: Phoenix Molecular Imaging | Conditions: Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Status: COMPLETED